Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients

Transplantation

Volumn 97, Issue 6, 2014, Pages 612-617

  Brokhof, Marissa M ^a   Sollinger, Hans W ^b   Hager, David R ^a   Muth, Brenda L ^b   Pirsch, John D ^b   Fernandez, Luis A ^b   Bellingham, Janet M ^b   Mezrich, Joshua D ^b   Foley, David P ^b   D'alessandro, Anthony M ^b   Odorico, Jon S ^b   Mohamed, Maha A ^b   Vidyasagar, Vijay ^b   Ellis, Thomas M ^a   Kaufman, Dixon B ^b   Djamali, Arjang ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antibody mediated rejection; Basiliximab; Donor specific antibody; Sensitization; Thymoglobulin

Indexed keywords

BASILIXIMAB; CREATININE; HLA ANTIBODY; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY; DE NOVO DONOR SPECIFIC ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BK VIRUS INFECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; EDITORIAL; MAINTENANCE THERAPY;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; ISOANTIGENS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897023520     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000031     Document Type: Article

References (19)

1. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J AmSocNephrol 2012; 23: 2061.
2. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
3. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
4. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
5. Lefaucheur C, Suberbielle-Boissel C, Hill CS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
6. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103.
7. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
8. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
9. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trail. Am J Transplant 2004; 4: 438.
10. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95; 19.
11. Thibaudin D, Alamartine E, de Filippis JP, et al. Advantages of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: 711.
12. Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385.
13. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
14. Ayasoufi K, Yu H, Fan R, et al. Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactice memory T cells in mice. Am J Transplant 2013; 13: 589.
15. Todeschini M, Cortinovis M, Perico N, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit antithymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol 2013; 191: 2818.
16. Krystufkova E, Sekerkova A, Striz I, et al. Regulatory T cells in kidney transplant recipients: The effect of induction immunosuppression therapy. Nephrol Dial Transplant 2012; 27: 2576.
17. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132.
18. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: The University of Wisconsin initial experience. Transplantation 2011; 92: 12.
19. Sis B, Mengel M, Haas M, et al. Banff '09 Meeting Report: Antibody mediated graft deterioration and implementation of banff working groups. Am J Transplant 2010; 10: 464.